Clinical Trials Directory

Trials / Completed

CompletedNCT03113786

CLARIX™ 100 & CLARIX CORD 1K for Discectomy Patients

Efficacy of Amniotic Tissue (CLARIX 100 & CLARIX CORD 1K) in Pain Reduction and Improvement of Function in Low Back & Leg Pain in Discectomy Patients

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
32 (actual)
Sponsor
Amniox Medical, Inc. · Industry
Sex
All
Age
18 Years – 90 Years
Healthy volunteers
Not accepted

Summary

The purpose of the study is to evaluate the efficacy of CLARIX™ 100 and CLARIX™ CORD 1K as a tissue barrier when used as an annular patch in discectomy patients with low back \& leg pain when compared to traditional discectomy patient outcomes. This will be a 120 patient, prospective randomized study model over a 5 year post-operative period.

Conditions

Interventions

TypeNameDescription
OTHERCLARIX™100CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
OTHERCLARIX CORD 1KCLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues \& Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.

Timeline

Start date
2011-11-02
Primary completion
2020-04-21
Completion
2020-04-21
First posted
2017-04-14
Last updated
2020-07-15

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03113786. Inclusion in this directory is not an endorsement.